EC Number   |
Application |
Reference |
|---|
   2.3.1.26 | analysis |
use of inhibitor K-604, selective for isoform ACAT-1, to measure the individual enzymatic activities of isoforms ACAT-1 and ACAT-2 in semniferous tubule |
705528 |
| 2.3.1.26 | drug development |
regulation of ACAT1 activities in hepatic stellate cells can be a target for treatment of liver fibrosis |
-, 736580 |
| 2.3.1.26 | drug development |
selective inhibitors of the cholesterol esterifying enzyme sterol-O acyltransferase 2 (SOAT2) hold great promise as effective atherosclerotic cardiovascular disease therapeutics |
736719 |
| 2.3.1.26 | drug development |
the enzyme is a potential target for treating hypercholesterolemia |
736178 |
| 2.3.1.26 | drug development |
the enzyme is regarded as a potential therapeutic target for cardiovascular diseases |
736937 |
| 2.3.1.26 | medicine |
a panel of ovarian cancer cell lines (OC-314, SKOV-3 and IGROV-1) displays significant increase in the expression of ACAT1 and cholesterol ester levels compared to primary ovarian epithelial cells. ACAT1 knockdown ovarian cancer cell lines show significant suppression of cell proliferation, migration and invasion compared to their respective controls. ACAT-1 inhibition enhances apoptosis with a concurrent increase in caspases 3/7 activity and decreased mitochondrial membrane potential, and ACAT1-inhibited ovarian cancer cell lines display enhanced chemosensitivity to cisplatin treatment |
758187 |
| 2.3.1.26 | medicine |
ACAT is a key enzyme in controlling cholesterol metabolism and represents a promising target for the development of therapeutic agents and inhibitors to control hypercholesterolemia, atherosclerosis and Alzheimer's disease |
672617 |
| 2.3.1.26 | medicine |
an anti-oxidative ACAT inhibitor or the combination of an antioxidant and an ACAT inhibitor protects foam cells from oxidative stress and effectively reduces cholesterol levels, which would be a promising approach in anti-atherosclerotic therapy |
688767 |
| 2.3.1.26 | medicine |
elevated ACAT2expression may serve as a new biomarker for certain forms of hepatocellular carcinoma |
671850 |
| 2.3.1.26 | medicine |
feeding a diet suplemented with linoleic acid, conjugated linoleic acid, alpha-linolenic acid or conjugated linolenic acid results in decrease in plasma cholesterol, with conjugated linoleic acid being the most effective. Diets have no effect on sterol regulatory element binding protein-2, liver X receptor, 3-hydroxy-3-methylglutary-CoA reductase, LDL receptor, and cholesterol-7-hydroxylase. The four octadecaenoic acids increase the excretion of fecal neutral sterols with conjugated linoleic acid being most effective followed by alphga-linolenic acid, linoleic acid and conjugated linolenic acid. Dietary conjugated linoleic acid is associated with the least intestinal acyl coenzyme A: cholesterol acyltransferase activity followed by alpha-linolenic acid, linoleic acid and conjugated linolenic acid in a decreasing trend |
701988 |
